Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Lumenis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lumenis and Bloomage Biotech jointly released a new product - M22 medical wound dressing
Details : M22 medical wound dressing (sodium hyaluronate) is a versatile laser treatment system based on Lumenis' medical beauty concept of "30% Laser Treatment and 70% Postoperative care.
Product Name : M22 Medical Wound Dressing
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2023
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Lumenis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Licensing Agreement
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
Details : Under the agreement, BioSyent extended its agreement with its European partner for RepaGyn (sodium hyaluronate) and Proktis-M, extending its exclusive Canadian rights to these products until 2032.
Product Name : Repagyn
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 15, 2024
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Sodium Hyaluronate,Triamcinolone Hexacetonide
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anika’s Cingal® Successfully Achieves Primary Endpoint in Third Phase III Study
Details : Cingal (sodium hyaluronate) combination product of cross-linked hyaluronic acid (HA) proven to provide long lasting pain relief through 6 months plus TH steroid to provide fast, short-term pain relief.
Product Name : Cingal
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : Sodium Hyaluronate,Triamcinolone Hexacetonide
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : I-MED
Deal Size : Undisclosed
Deal Type : Partnership
Details : NTC and I-MED Pharma’s successful collaboration to bring I-DEFENSE® innovative ophthalmic ointment first to Canada and now to the U.S.A. is a testament to the dedication of both companies to advancing the science of dry eye.
Product Name : I-Defense
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 15, 2021
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : I-MED
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NIH Study Shows Hyaluronan is Effective in Treating Chronic Lung Disease
Details : Researchers at the National Institutes of Health and their collaborators found that inhaling unfragmented hyaluronan improves lung function in patients suffering from severe exacerbation of chronic obstructive pulmonary disease (COPD).
Product Name : HMW-HA
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2021
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LOA2 met its primary endpoint of non-inferiority vs. comparator at the 3-month time point in corneal staining with a p value of 0.001. LO2A continued, as in prior trials, to demonstrate a good safety profile with no major adverse events or side effects r...
Product Name : LO2A
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The clinical trial is designed to demonstrate the clinical efficacy and safety of LO2A in DES patients with Sjögren's syndrome. Phase IV study aims at expanding LO2A's current approved status.
Product Name : LO2A
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 05, 2020
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Bonus BioGroup
Deal Size : $7.4 million
Deal Type : Agreement
Wize Pharma Executes Agreements for Strategic Transaction with Bonus BioGroup
Details : This agreement will advance Wize Pharma's ongoing clinical program for LO2A, currently in a Phase IV study for the treatment of dry eye syndrome in patients with Sjogren's.
Product Name : LO2A
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 16, 2020
Lead Product(s) : Sodium Hyaluronate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Bonus BioGroup
Deal Size : $7.4 million
Deal Type : Agreement
Reset All
Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.
